Scienture Holdings Inc

Scienture Holdings Inc has a market capitalization of $16.7 million and a price-to-earnings ratio of 0.79, indicating a relatively low valuation compared to earnings. The company's price-to-book ratio is 1.23, suggesting that the market value is slightly above the book value of its equity. The company's liquidity position is characterized by a current ratio of 4.75, which is significantly above the industry median, indicating strong short-term liquidity. However, the company has no long-term debt, and its debt-to-equity ratio is 0.0, reflecting a conservative capital structure.

In terms of profitability, the company reported a net income of $21.25 million, but this was offset by an operating loss of $5.49 million, indicating that operational efficiency is a concern. The return on equity (ROE) is 1.56, and the return on assets (ROA) is 1.27, both of which are below the industry median, suggesting that the company is not generating strong returns relative to its equity and asset base. The company's operating cash flow is negative at -$10.19 million, and its free cash flow is -$21.80 million, indicating that the company is not generating sufficient cash from operations to fund its activities.

The company's revenue is reported as $0.00, which is a significant concern and suggests that the company may not have a viable revenue stream at this time. The company's capital expenditure of -$2.50 million indicates that it is investing in its operations, but the lack of revenue raises questions about the sustainability of these investments. The company's geographic exposure is not disclosed, but the absence of revenue data suggests that the company may be in an early stage of development or may be facing significant market challenges.

Looking ahead, the company's growth trajectory is uncertain. The lack of revenue and the negative operating cash flow suggest that the company may need to secure additional financing to continue operations. The company's liquidity position is currently strong, with a current ratio of 4.75, but the negative free cash flow indicates that this may not be sustainable in the long term. The company's risk assessment indicates low liquidity and dilution risk, but the absence of revenue and the negative operating cash flow suggest that the company may face significant financial challenges in the future.

Recent events and filings do not indicate any immediate liquidity or dilution risks, but the company's financial performance raises concerns about its long-term viability. The company's capital structure is currently debt-free, but the need for additional financing may lead to increased leverage in the future. The company's profitability metrics are weak, and the lack of revenue suggests that the company may need to pivot its business model or secure new revenue streams to remain competitive.

Scienture Holdings Inc (SCNX.O) has recorded three notable additions to its shareholder base, marking the first available analysis for the ticker. These changes were detected on June 20, 2026, and involve new institutional positions established as of late 2025 and early 2026. The most significant addition occurred as of December 31, 2025, when investor ID 465 acquired 606,151 shares, valued at approximately $0.31 million. Two additional investors also initiated positions as of March 31, 2026. Investor ID 499 added 107,833 shares, representing a value of roughly $0.03 million, while investor ID 502 acquired a smaller stake of 13,894 shares, valued at approximately $0.004 million. These entries reflect a modest but distinct accumulation of shares by new holders during the first half of 2026. The significance of these moves lies in the establishment of a baseline for ownership structure, as there is no prior data for delta computation. With only four top holders currently identified and no analyst coverage or index membership recorded, these new positions represent the initial layer of institutional interest in the company. The lack of prior basis for comparison makes these additions the primary reference point for future tracking of shareholder activity. Currently, Scienture Holdings Inc operates with no reported officers and zero analyst estimates, suggesting a limited public profile or early-stage reporting status. The emergence of these three new holders provides the first concrete data points regarding external investment interest, offering a starting framework for monitoring potential shifts in ownership concentration or institutional engagement in the coming quarters.

Analysts project 268% upside to a $1.50 target price, signaling strong potential for significant share price appreciation.

Return on equity of 1.56% significantly outperforms the pharmaceutical cohort median of 0.029%, indicating superior capital efficiency.

The company maintains a low debt-to-equity ratio of 0.20, suggesting a conservative capital structure with manageable leverage risk.

A current ratio of 2.89 indicates strong short-term liquidity, providing ample buffer to meet immediate financial obligations.

Dilution and liquidity risks are assessed as low, reducing immediate threats to shareholder value and market stability.

Free cash flow deteriorated to -$35.6 million, highlighting a massive cash burn that threatens long-term financial sustainability.

The company faces high credit risk, signaling potential difficulties in meeting debt obligations or securing favorable financing terms.

Return on invested capital is negative at -0.40%, demonstrating an inability to generate adequate returns on deployed capital.

Cash conversion is in the bottom quartile of the pharmaceutical cohort, indicating poor efficiency in turning operations into cash.

Revenue $431.6k, +215,9% YoY; Operating income −149,6% YoY.

• ▍Revenue $431.6k, +215,9% YoY
• ▍Operating income −149,6% YoY
• ▍Net income −557,9% YoY
• ▍Free cash flow −15,3% YoY
• ▍Net margin -9618.0%

Revenue $1.4M, −86,7% YoY; Operating income −50,8% YoY.

• ▍Revenue $1.4M, −86,7% YoY
• ▍Operating income −50,8% YoY
• ▍Net income −413,9% YoY
• ▍Free cash flow −220,0% YoY
• ▍Net margin -1308.3%

Revenue $10.3M, +3,6% YoY; Operating income +44,9% YoY.

• ▍Revenue $10.3M, +3,6% YoY
• ▍Operating income +44,9% YoY
• ▍Net income +34,7% YoY
• ▍Free cash flow +55,2% YoY
• ▍Net margin -33.9%

Revenue $9.9M; Operating income -$5.3M.

• ▍Revenue $9.9M
• ▍Operating income -$5.3M
• ▍Net margin -53.8%